Mass gathering preparedness: The experience of the Athens 2004 olympic and Para-Olympic games

Planning for environmental health management of the Athens 2004 Olympic Games included assessment of the capacity and deficiencies of relevant public health agencies in Athens and the other four Olympic cities with 17 detailed questionnaires. Different estimates of the expected number of visitors were made on the basis of experience from previous Olympic Games. Potential public health risk were identified and prioritized. A number of deficiencies in personnel, resources, training, and coordination were identified in most agencies. One hundred and ninety-six environmental health inspectors were expected to work during the Olympic period. Around 18,000 athletes and escorts from 201 countries were expected to participate in the Olympic Games and 7,000 to participate in the Para-Olympic Games. Three different scenarios regarding the number of expected visitors were explored; the most probable estimate being 1,950,000 visitors. Foodborne diseases, waterborne diseases, and heat-related illnesses were considered of high priority during the Olympic period, as were traffic accidents. The Olympic Games are a difficult assignment that demands extensive planning, appropriate resources, and timely reporting and coordination among the various public health agencies

Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network across Rural Greece: The Grecoself study

Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25-29 years to 5.1% for women aged 50-60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25-29) to 76.3% (for women 40-49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention. ©2019 American Association for Cancer Research

Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network across Rural Greece: The Grecoself study

Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25-29 years to 5.1% for women aged 50-60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25-29) to 76.3% (for women 40-49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention. ©2019 American Association for Cancer Research